Loading patent…
AssigneePfizer Inc.
InventorsEmilio Anthony Emini, Wendy Jo Watson, Avvari Krishna Prasad, Mingming Han, Jin-Hwan Kim, Jianxin Gu, Yu-ying Yang, Rajesh Kumar Kainthan, David Cooper, Michael William Pride, Kathrin Ute Jansen
Estimating the term…
The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
1-287. (canceled)
A method of preventing, treating or ameliorating a disease or condition associated with Streptococcus pneumoniae infection in a human subject, comprising administering to said subject an immunologically effective amount of a 21-valent immunogenic composition comprising glycoconjugates of capsular polysaccharide from Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F individually conjugated to a carrier protein, wherein the carrier protein of the glycoconjugates respectively comprising capsular polysaccharide of serotypes 8, 10A, 11A, 12F and 33F is CRM197, and wherein the carrier protein of the glycoconjugates respectively comprising capsular saccharide of serotypes 15B and 22F is tetanus toxoid.
A method of inducing an immune response against Streptococcus pneumoniae in a subject, comprising administering to said subject an immunologically effective amount of a 21-valent immunogenic composition comprising glycoconjugates of capsular polysaccharide from Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F individually conjugated to a carrier protein, wherein the carrier protein of the glycoconjugates respectively comprising capsular polysaccharide of serotypes 8, 10A, 11A, 12F and 33F is CRM197, and wherein the carrier protein of the glycoconjugates respectively comprising capsular saccharide of serotypes 15B and 22F is tetanus toxoid.
Dependencies are inferred from the claim text.